alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
_________________________________________ 

 

 

 

Order Michigan Supreme Court 

Lansing, Michigan 

March 27, 2006 Clifford W. Taylor,

 Chief Justice 

129850 & (13) Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

Maura D. Corrigan 

Robert P. Young, Jr. PEOPLE OF THE STATE OF MICHIGAN, Stephen J. Markman, Plaintiff-Appellee, Justices 

v SC: 129850 

 COA: 264485 
 Wayne CC: 04-002400-01 

DALION LAMARR DAVIS,

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the September 15, 2005 

order of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the question presented should be reviewed by this Court. The motion to 

remand is DENIED. 

p0320 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

March 27, 2006 

Clerk
```

[Federal Register Volume 75, Number 37 (Thursday, February 25, 2010)]
[Notices]
[Page 8648]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3776]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

    The Department of Commerce will submit to the Office of Management 
and Budget (OMB) for clearance the following proposal for collection of 
information under the provisions of the Paperwork Reduction Act (44 
U.S.C. Chapter 35).
    Agency: Economic Development Administration (EDA).
    Title: Petition by a Firm for Certification of Eligibility to Apply 
for Trade Adjustment Assistance.
    OMB Control Number: 0610-0091.
    Form Number(s): ED-840P.
    Type of Request: Regular submission.
    Number of Respondents: 800.
    Average Hours per Response: 128 hours, 12 minutes.
    Burden Hours: 40,101.
    Needs and Uses: The information contained in Form ED-840P is 
necessary for EDA to evaluate whether proposed projects satisfy 
eligibility and programmatic requirements contained in chapters 3 and 5 
of title II of the Trade Act of 1974, as amended (19 U.S.C. 2341 et 
seq.) and the Trade and Globalization Adjustment Assistance Act (TGAAA) 
of 2009 which reauthorized the program.
    Affected Public: Business or other for-profit organizations.
    Frequency: On occasion.
    Respondent's Obligation: Mandatory.
    OMB Desk Officer: Sharon Mar, (202) 395-6466.
    Copies of the above information collection proposal can be obtained 
by calling or writing Diana Hynek, Departmental Paperwork Clearance 
Officer, (202) 482-0266, Department of Commerce, Room 6625, 14th and 
Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at 
[email protected]).
    Written comments and recommendations for the proposed information 
collection should be sent within 30 days of publication of this notice 
to Sharon Mar, OMB Desk Officer, FAX number (202) 395-5806, or [email protected].

    Dated: February 19, 2010.
Gwellnar Banks,
Management Analyst, Office of the Chief Information Officer.
[FR Doc. 2010-3776 Filed 2-24-10; 8:45 am]
BILLING CODE 3510-24-P
```
§ 522.533 Deslorelin. ( a ) *Specifications.* ( 1 ) Each implant contains 2.1 milligrams (mg) deslorelin acetate.
( 2 ) Each milliliter (mL) of suspension contains 1.8 mg deslorelin acetate.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter as follows: ( 1 ) No. 051311 for use of product described in paragraph (a)(1) as in paragraph (c)(1) of this section.
( 2 ) No. 043264 for use of product described in paragraph (a)(2) as in paragraph (c)(2) of this section.
( c ) *Conditions of use* — ( 1 ) *Horses and ponies* — ( i ) *Amount.* One implant per mare subcutaneously in the neck.
( ii ) *Indications for use.* For inducing ovulation within 48 hours in estrous mares with an ovarian follicle greater than 30 millimeters (mm) in diameter.
( iii ) *Limitations.* Do not use in horses or ponies intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Horses* — ( i ) *Amount.* Administer 1.8 mg (1 mL) by intramuscular injection in the neck.
( ii ) *Indications for use.* For inducing ovulation within 48 hours in cyclic estrous mares with an ovarian follicle between 30 and 40 mm in diameter.
( iii ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[75 FR 81456, Dec. 28, 2010, as amended at 79 FR 18158, Apr. 1, 2014; 87 FR 17945, Mar. 29, 2022; 87 FR 58962, Sept. 29, 2022]
###### Editorial Note on Part 314

#### Editorial Note:

Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

#### § 314.630 Postmarketing safety reporting.

Drug products approved under this subpart are subject to the postmarketing recordkeeping and safety reporting requirements applicable to all approved drug products, as provided in §§ 314.80 and 314.81.
#### § 520.154 Bacitracin oral dosage forms.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                       7,874,836
<SECURITIES>                                         0
<RECEIVABLES>                                  157,369
<ALLOWANCES>                                         0
<INVENTORY>                                  3,400,706
<CURRENT-ASSETS>                            23,361,385
<PP&E>                                      10,953,783
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              34,544,999
<CURRENT-LIABILITIES>                       16,897,879
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       495,529
<OTHER-SE>                                  17,151,591
<TOTAL-LIABILITY-AND-EQUITY>                34,544,999
<SALES>                                     45,348,715
<TOTAL-REVENUES>                            45,348,715
<CGS>                                       24,105,665
<TOTAL-COSTS>                               44,990,393
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                703,527
<INCOME-TAX>                                   253,000
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   450,527
<EPS-PRIMARY>                                     0.10
<EPS-DILUTED>                                     0.10
        

</TABLE>
June 24, 2015

Mr. Rick Kaplan Sherpa Productions, Inc.

395 South End Avenue New York, NY 10280

Dear Mr. Kaplan:

This letter is to inform you that we are unable to process your request for an exemption from Title 14, Code of Federal Regulations (14 CFR) . It explains why we can not process your request and what you should do in the next 30 days.

Why We Can Not Process Your Request

We entered your June 11, exemption request on behalf of Sherpa Productions, Inc. into the public docket (No. FAA-2015-2233), but we are unabl e to process your request any further. The information you sent does not comply with the requirements of § 11.81 (copy enclosed). For us to consider the request any further, you must send us all of the following:

 The specific section or sections of 14 CFR from which you seek relief, the extent of the relief you seek, and the reason you seek relief.

 The reasons why granting the request would be in the public interest; that is, how it would benefit the public as a whole.

 The reasons why the exemption would not adversely affect safety or how the exemption would provide a level of safety at least equal to that provided by the rule from which you seek an exemption.

 Any additional information, views, or arguments available to support your request.2

What You Should Do

If you want us to process your request any further, you must send the information described earlier to reach us within 30 days. Please note that § 11.63(d) requires you to send your petition for exemption at least 120 days before the proposed effective date of the exemption.

If We Do Not Hear From You

If we do not hear from you within 30 days, we will close the docket without notifying you further. If you have any questions or require additional time, you may call (202) 267-9677.

Sincerely,

/s/

Brenda Robeson Program Analyst, Airmen and Airspace Rules Division

Enclosure
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     (Replace this text with the legend)
</LEGEND>
<CIK>                         0000813621                                        
<NAME>                        AMCOL INTERNATIONAL CORPORATION                   
<MULTIPLIER>                                   1,000
<CURRENCY>                                     USD
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-1997  
<PERIOD-START>                                 JAN-01-1997
<PERIOD-END>                                   MAR-31-1997
<EXCHANGE-RATE>                                1.00
<CASH>                                         5,172
<SECURITIES>                                   0
<RECEIVABLES>                                  80,522
<ALLOWANCES>                                   2,850
<INVENTORY>                                    60,296
<CURRENT-ASSETS>                               149,868
<PP&E>                                         302,623
<DEPRECIATION>                                 124,258
<TOTAL-ASSETS>                                 348,849
<CURRENT-LIABILITIES>                          53,764
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       213
<OTHER-SE>                                     0
<TOTAL-LIABILITY-AND-EQUITY>                   348,849
<SALES>                                        107,918
<TOTAL-REVENUES>                               107,918
<CGS>                                          86,107
<TOTAL-COSTS>                                  100,614
<OTHER-EXPENSES>                               105
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             2,162
<INCOME-PRETAX>                                5,037
<INCOME-TAX>                                   1,864
<INCOME-CONTINUING>                            3,173
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   3,173
<EPS-PRIMARY>                                  .16
<EPS-DILUTED>                                  .16
        


</TABLE>
§ 344.52 Labeling of ear drying aid drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as an “ear drying aid.”
( b ) *Indications.* The labeling of the product states, under the heading “Use,” the following: “dries water in the ears” (optional, which may be followed by: “and relieves water-clogged ears”) (which may be followed by any or all of the following: “after: [bullet][1] swimming [bullet] showering [bullet] bathing [bullet] washing the hair”). Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in paragraph (b) of this section, may also be used, as provided in § 330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (the act) relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.
( c ) *Warnings.* The labeling of the product contains the following warnings under the heading “Warnings”: ( 1 ) “Flammable [in bold type]: Keep away from fire or flame.”
( 2 ) “Do not use [in bold type] in the eyes.”
( 3 ) “Ask a doctor before use if you have [in bold type] [bullet] ear drainage or discharge [bullet] pain, irritation, or rash in the ear [bullet] had ear surgery [bullet] dizziness.”
( 4 ) “Stop use and ask a doctor if [in bold type] irritation (too much burning) or pain occurs.”
( d ) *Directions.* The labeling of the product contains the following statement under the heading “Directions”: [optional, bullet] “apply 4 to 5 drops in each affected ear.”
[65 FR 48905, Aug. 10, 2000] Footnotes -
344.52
[1] See § 201.66(b)(4) of this chapter.
The State of



# Fourth Court of Appeals

**San Antonio, Texas**

July 3, 2014

N o. 04

- 13

- 00831

- CR

Douglas Oneil BARNES

, Appellant

v.

The STATE of Texas, Appellee

From the 198th Judicial District Court, Bandera County, Texas

Trial Court No. CR13

- 001 Honorable M. Rex Emerson, Judge Presiding



### ORDER

On March 18, 2014, appellant’s court

- appointed counsel filed a brief and a first amended

motion to withdraw in accordance with Anders v. California , 386 U.S. 738 (1967). On March 21, 2014, we issued an order advising appellant of his right to file his own brief and giving appellant forty

- five (45) days from the date of our order to file any pro se brief. A ppellant did not file a pro se brief within t he time provided . T his appeal was therefore ready to be submitted to the court.

However, o n June 25, 2014, before this appeal was set for submission

, the Texas Court of Criminal Appeals instructed that court

- appointed counsel who files an Anders brief must “take concrete measures to initiate and facilitate the process of actuating his client’s right to review the appellate record, if that is what his client wishes.” Kelly v. State , No. 0702

- 13, 2014 WL 2865901, at * 3 (Tex. Crim. App. 2014). The Court of Criminal Appeals further instruct ed that

when an appellant files a motion for access to the appellate record, the court of appeals must specify the procedure for an appellant to obtain the record in that particular case. Id ., at * 4.

In lig ht of the post ure of this appeal, appellant is advise d that if he desires to

exercise his right to review the appellate record , he must file a written request for access to the record with this court by July 17, 2013

. Any such request must reference this appeal and

be mailed to:

Fourth Court of Appeals 300 Dolorosa, Suite 3200 San Antonio, Texas 78232If appellant timely requests access to the record, the deadline to file appellant’s pro se

brief will be reset. Otherwise , this case will be set for submission to the court.

_________________________________ Karen Angelini, Justice

IN WITNESS WHEREOF, I hav e hereunto set my hand and affixed the seal of the said

court on this 3rd day of July, 2014

.

___________________________________ Keith E. Hottle

Clerk of Court
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                           1,083
<SECURITIES>                                         0
<RECEIVABLES>                                      331
<ALLOWANCES>                                      (44)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 1,687
<PP&E>                                           1,223
<DEPRECIATION>                                   (218)
<TOTAL-ASSETS>                                   4,002
<CURRENT-LIABILITIES>                              703
<BONDS>                                          2,552
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            18
<OTHER-SE>                                         110
<TOTAL-LIABILITY-AND-EQUITY>                     4,002
<SALES>                                              8
<TOTAL-REVENUES>                                   852
<CGS>                                                4
<TOTAL-COSTS>                                      524
<OTHER-EXPENSES>                                   762
<LOSS-PROVISION>                                    38
<INTEREST-EXPENSE>                                 209
<INCOME-PRETAX>                                  (599)
<INCOME-TAX>                                        18
<INCOME-CONTINUING>                              (617)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (617)
<EPS-BASIC>                                     (3.76)
<EPS-DILUTED>                                   (3.76)


</TABLE>
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.304 Tannic acid and barium enema preparations. ( a ) It has become a widespread practice for tannic acid to be added to barium enemas to improve X-ray pictures. Tannic acid is capable of causing diminished liver function and severe liver necrosis when absorbed in sufficient amounts. The medical literature reports a number of deaths associated with the addition of tannic acid to barium enemas. There is a lack of scientific evidence to establish the conditions, if any, under which tannic acid is safe and effective for use in enemas. Tannic acid for rectal use to enhance X-ray visualization is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act.
( b ) In view of the hazards involved when tannic acid is used in barium enemas, any shipments of tannic acid labeled to come within the exemptions under 502(f) of the Act containing such phrases as: “Caution: For manufacturing, processing, or repackaging,” “For prescription compounding,” or “Diagnostic reagent—For professional use only” will be regarded by the Commissioner of Food and Drugs as misbranded within the meaning of section 502(f) of the Federal Food, Drug, and Cosmetic Act unless the label and the labeling bear conspicuously a warning to the effect: “*Warning—* Not for use in enemas.”
( c ) Any tannic acid intended for use by man and found within the jurisdiction of the Federal Food, Drug, and Cosmetic Act labeled contrary to this section after 60 days from the date of its publication in the Federal Register may be made the subject of regulatory proceedings.
* Pursuant to 5th Cir. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5th Cir. R.

47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 97-30948

 

UNITED STATES OF AMERICA

Plaintiff-Appellee

versus

BILLY DOUGLAS

Defendant-Appellant

 

Appeal from the United States District Court

For the Middle District of Louisiana 

(97-CR-5)

 

November 4, 1998

Before HIGGINBOTHAM, DAVIS, and BARKSDALE, Circuit Judges.

PER CURIAM:*

AFFIRMED. See Local Rule 47.6.
<TABLE> <S> <C>

<ARTICLE> UT
<LEGEND>
This schedule  contains summary  financial  information  extracted from the Form
10-K for  December  31,  1996,  and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<CIK> 0000948362
<NAME> MOBILE ENERGY SERVICES CO LLC
       
<S>                                 <C>
<PERIOD-TYPE>                       YEAR
<FISCAL-YEAR-END>                                             DEC-31-1996
<PERIOD-END>                                                  DEC-31-1996
<BOOK-VALUE>                                                  PER-BOOK
<TOTAL-NET-UTILITY-PLANT>                                     354,889
<OTHER-PROPERTY-AND-INVEST>                                   0
<TOTAL-CURRENT-ASSETS>                                        54,661
<TOTAL-DEFERRED-CHARGES>                                      14,188
<OTHER-ASSETS>                                                0
<TOTAL-ASSETS>                                                423,738
<COMMON>                                                      0
<CAPITAL-SURPLUS-PAID-IN>                                     0
<RETAINED-EARNINGS>                                           62,908
<TOTAL-COMMON-STOCKHOLDERS-EQ>                                62,908
<PREFERRED-MANDATORY>                                         0
<PREFERRED>                                                   0
<LONG-TERM-DEBT-NET>                                          303,811
<SHORT-TERM-NOTES>                                            0
<LONG-TERM-NOTES-PAYABLE>                                     0
<COMMERCIAL-PAPER-OBLIGATIONS>                                0
<LONG-TERM-DEBT-CURRENT-PORT>                                 (7,350)
<PREFERRED-STOCK-CURRENT>                                     0
<CAPITAL-LEASE-OBLIGATIONS>                                   0
<LEASES-CURRENT>                                              0
<OTHER-ITEMS-CAPITAL-AND-LIAB>                                57,019
<TOT-CAPITALIZATION-AND-LIAB>                                 423,738
<GROSS-OPERATING-REVENUE>                                     84,058
<INCOME-TAX-EXPENSE>                                          0
<OTHER-OPERATING-EXPENSES>                                    45,988
<TOTAL-OPERATING-EXPENSES>                                    45,988
<OPERATING-INCOME-LOSS>                                       38,070
<OTHER-INCOME-NET>                                            942
<INCOME-BEFORE-INTEREST-EXPEN>                                39,012
<TOTAL-INTEREST-EXPENSE>                                      30,094
<NET-INCOME>                                                  8,918
<PREFERRED-STOCK-DIVIDENDS>                                   0
<EARNINGS-AVAILABLE-FOR-COMM>                                 8,918
<COMMON-STOCK-DIVIDENDS>                                      0
<TOTAL-INTEREST-ON-BONDS>                                     0
<CASH-FLOW-OPERATIONS>                                        24,055
<EPS-PRIMARY>                                                 0
<EPS-DILUTED>                                                 0
        



</TABLE>
-78.5 -78.0 -77.5 -77.0 -76.5

 38.5

 39.0

 39.5

★

▲

▲

▲

▲

★

▲ ▲ ▲ ▲

 500

 1000

 1500

 500

18 12 06 00

07/08

NOAA HYSPLIT MODEL

 Backward trajectory ending at 2300 UTC 08 Jul 07

 EDAS Meteorological Data

Source

★ at 38.90 N 76.65 W Meters AGL